GSK_ Annual_Report_2021-22

135 Notes to the Standalone Financial Statements for the year ended March 31, 2022 Note 18 : Equity Share Capital ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 Authorised 18,00,00,000 (March 31, 2021: 18,00,00,000) equity shares of ` 10 each 180,00.00 180,00.00 Issued 16,94,15,420 (March 31, 2021: 16,94,15,420) equity shares of ` 10 each 169,41.54 169,41.54 Subscribed and Paid-Up 16,94,06,034* (March 31, 2021: 16,94,06,034) equity shares of ` 10 each, fully paid up 169,40.60 169,40.60 169,40.60 169,40.60 * excludes 9,386 (March 31, 2021: 9,386) equity shares of ` 10 each of the Company (3,352 equity shares of ` 10 each of erstwhile Burroughs Wellcome (India) Limited) held in abeyance. ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 Number of Shares ` in lakhs Number of Shares ` in lakhs a) Reconciliation of the number of shares Balance at the beginning of the year 16,94,06,034 169,40.60 16,94,06,034 169,40.60 Balance at the end of the year 16,94,06,034 169,40.60 16,94,06,034 169,40.60 b) Rights, preferences and restrictions attached to equity shares: The Company has one class of equity shares having a par value of ` 10 per share. Each shareholder is eligible for one vote per share held. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding. c) Shares held by promoters of Company Sr. No. Promoter’s Name FY 2021-22 % change during the year No. of Shares % of total shares (i) Glaxo Group Limited, U.K. 6,09,70,500 35.99% - (ii) Eskaylab Limited, U.K. 1,17,60,000 6.94% - (iii) Burroughs Wellcome International Limited 67,20,000 3.97% - (iv) GlaxoSmithKline Pte Limited, Singapore 4,76,04,024 28.10% - d) Shares held by subsidiaries of ultimate holding company in aggregate ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 Number of Shares ` in lakhs Number of Shares ` in lakhs Equity shares of ` 10 each (representing 75.00% of total shareholding) 12,70,54,524 127,05.46 12,70,54,524 127,05.46 e) Details of equity shares held by shareholders holding more than 5% shares of the aggregate shares in the Company: ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 Number of Shares % Shareholding Number of Shares % Shareholding Glaxo Group Limited, U.K. 6,09,70,500 35.99% 6,09,70,500 35.99% GlaxoSmithKline Pte Limited, Singapore 4,76,04,024 28.10% 4,76,04,024 28.10% Eskaylab Limited, U.K. 1,17,60,000 6.94% 1,17,60,000 6.94% Life Insurance Corporation of India 76,95,698 4.54% 80,91,878 4.78%